The Government Accountability Office yesterday released a report examining the characteristics of hospitals that participate in the 340B drug savings program and hospitals that do not participate in the program. The report focused on critical access hospitals, sole community hospitals and general acute care hospitals that treat a disproportionate share of low-income patients because these types accounted for more than 95% of hospitals participating in the program in 2016. Among other findings, GAO found that in 2016 “compared with non-340B hospitals, 340B hospitals generally provided similar amounts of charity care and higher amounts of uncompensated care – which typically represent services that hospitals provide to patients who are unable or unwilling to pay for their care, respectively.” The report also found that from 2012 to 2016 disproportionate share hospitals’ participation in the 340B program increased in states that expanded Medicaid under the Affordable Care Act, while 340B participation did not increase for those hospitals in non-expansion states. 
 
 

Related News Articles

Headline
Rep. Doris Matsui, D-Calif., and Sen. Peter Welch, D-Vt., today introduced the 340B Patients Act, AHA-supported legislation that would codify 340B providers'…
Headline
The Congressional Budget Office today released its estimate of the budgetary effects of the One Big Beautiful Bill Act, as enacted. CBO projects the law will…
Headline
The Centers for Medicare & Medicaid Services July 17 issued two letters to states regarding policies on continuous eligibility and workforce initiatives.…
Headline
The AHA July 16 filed an amicus brief in the U.S. District Court for the District of Colorado in defense of the state’s 340B contract pharmacy law prohibiting…
Headline
Sen. Josh Hawley, R-Mo., July 15 introduced legislation that would repeal some of the Medicaid funding reductions included in the recently enacted One Big…
Headline
The U.S. District Court for the Eastern District of Missouri July 11 granted a motion by the state to dismiss claims by AbbVie that the state’s 340B contract…